2020
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D’Souza D, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 2020, 45: 990-997. PMID: 32092760, PMCID: PMC7162891, DOI: 10.1038/s41386-020-0644-9.Peer-Reviewed Original ResearchConceptsAntidepressant effectsKetamine administrationRapamycin pretreatmentMontgomery-Åsberg Depression Rating ScaleDouble-blind cross-over designBenefits of ketamineRobust antidepressant effectsKetamine's antidepressant effectsMajor depressive episodeDepression Rating ScaleCross-over designKetamine exertsOral rapamycinRemission rateDepressive episodePlacebo 2Ketamine 0.5Local blockadeDepressed patientsIntravenous administrationTreatment daysDepression relapseDepression severityKetamineRating Scale
2017
A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia
Gunduz‐Bruce H, Kenney J, Changlani S, Peixoto A, Gueorguieva R, Leone C, Stachenfeld N. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2017, 102: 587-597. PMID: 28294453, DOI: 10.1113/ep086212.Peer-Reviewed Original ResearchConceptsSubgroup of patientsHealthy control subjectsNMDA receptorsControl subjectsDepressed patientsAVP releaseAnimal studiesSchizophrenic subjectsTranslational approachVivo evidenceRecent clinical trialsNMDA receptor functionPlasma arginine vasopressin concentrationNMDA receptor activityHypertonic saline infusionNMDA antagonist ketamineArginine vasopressin concentrationHypertonic salineInverse associationClinical trialsHealthy controlsSaline infusionGlutamate signalingSchizophrenic patientsVasopressin concentration
2002
Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research 2002, 113: 245-254. PMID: 12559481, DOI: 10.1016/s0165-1781(02)00267-6.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTreatment-resistant depressed patientsDepressed patientsTherapeutic effectActive repetitive transcranial magnetic stimulationStimulation parametersTreatment-resistant depressionDouble-blind designTranscranial magnetic stimulationLeft prefrontal cortexSham groupMagnetic stimulationStimulation courseRTMS stimulationPatientsSystematic followThreshold stimulationPrefrontal cortexFollowPre-set criteriaSignificant differencesStimulationWork daysWeeksConsecutive work days